EC sanctions Celltrion’s Herzuma for breast Cancer patients
EU approval sought for treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer
European Commission extends approval to Celltrion’s Herzuma for treatment of patients with early breast Cancer, metastatic breast cancer or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification.
Woosung Kee, Chief Executive Officer of Celltrion claimed “We have already seen many benefits of biosimilars in Europe from our experience with Remsima and Truxima. Our experience has shown that biosimilars not only reduce individual patient’s out-of-pocket medical expenses but also contribute to lowering financial burden on insurance payers and national health agencies.”
The approval paves way for augmented treatment options for Celltrion. Herzuma is the third biosimilar from Celltrion’s portfolio approved by the EC.